Biogen
- All
- News
-
Alzheimer's Progression Slowed By Drug In Major Trial
Eisai Co. and partner Biogen Inc. said their Alzheimer's drug significantly slowed the disease, making it the first medicine to clearly blunt theprogression of the most common type of dementia in a definitive, large-scale trial.
-
Samsung in Talks to Buy Alzheimer’s Drug Maker Biogen for $42 Billion: Report
Biogen shares surged following a report that Samsung is in talks to acquire the US biotech company for more than $40 billion (roughly Rs. 2,98,170 crore).
-
Alzheimer's Progression Slowed By Drug In Major Trial
Eisai Co. and partner Biogen Inc. said their Alzheimer's drug significantly slowed the disease, making it the first medicine to clearly blunt theprogression of the most common type of dementia in a definitive, large-scale trial.
-
Samsung in Talks to Buy Alzheimer’s Drug Maker Biogen for $42 Billion: Report
Biogen shares surged following a report that Samsung is in talks to acquire the US biotech company for more than $40 billion (roughly Rs. 2,98,170 crore).
